Efficacy of Rifaximin in Preventing Campylobacteriosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

August 9, 2016

Study Completion Date

August 9, 2016

Conditions
DysenteryDiarrheaEnteric Campylobacteriosis
Interventions
BIOLOGICAL

Rifaximin intervention

Rifaximin administered then Challenge with C jejuni

BIOLOGICAL

Placebo intervention

Placebo administered then Challenge with C jejuni

Trial Locations (1)

21205

Center for Immunization Research, Johns Hopkins Bloomberg School of Public Heatlh, Baltimore

Sponsors
All Listed Sponsors
collaborator

Naval Medical Research Center

FED

collaborator

Uniformed Services University of the Health Sciences

FED

lead

Johns Hopkins Bloomberg School of Public Health

OTHER

NCT02280044 - Efficacy of Rifaximin in Preventing Campylobacteriosis | Biotech Hunter | Biotech Hunter